Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 7/20 | 0.65 |
| ▸ | THRA | P10827 | 6/20 | 0.65 |
| ▸ | RORC | P51449 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24407919 | 0.79 | THRB (0.70) | THRBTHRA | |
| SCHEMBL6903277 | 0.79 | THRA (0.77) | THRBTHRA | |
| SCHEMBL2925537 | 0.79 | THRB (1.00) | THRBTHRA | |
| SCHEMBL30083009 | 0.78 | THRB (0.40) | THRBTHRARORC | |
| SCHEMBL29066180 | 0.77 | THRB (0.41) | THRBTHRARORC | |
| SCHEMBL29527415 | 0.76 | RORC (0.67) | THRBTHRARORC | |
| SCHEMBL29066174 | 0.76 | RORC (0.67) | THRBTHRARORC | |
| SCHEMBL24407918 | 0.75 | THRB (0.40) | THRBTHRARORC | |
| SCHEMBL29527525 | 0.74 | THRB (0.38) | THRBTHRARORC | |
| SCHEMBL2921895 | 0.72 | THRA (0.67) | THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4240730-A1 | 2-PYRIDONES AS THYROID HORMONE RECEPTOR MODULATORS | Aligos Therapeutics, Inc. (US) | 2023-09-13 | — | — | EP | claimed |
| CN-116710443-A | 2-pyridones as thyroid hormone receptor modulators | 阿利戈斯治疗公司 | 2023-09-05 | — | — | CN | claimed |
| WO-2022099044-A1 | 2-PYRIDONES AS THYROID HORMONE RECEPTOR MODULATORS | ALIGOS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | claimed |
| US-11786532-B2 | 2-pyridones and methods of use thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11786532-B2 | 2-pyridones and methods of use thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| EP-4240730-A1 | 2-PYRIDONES AS THYROID HORMONE RECEPTOR MODULATORS | Aligos Therapeutics, Inc. (US) | 2023-09-13 | — | — | EP | disclosed |
| CN-116710443-A | 2-pyridones as thyroid hormone receptor modulators | 阿利戈斯治疗公司 | 2023-09-05 | — | — | CN | disclosed |
| WO-2022099044-A1 | 2-PYRIDONES AS THYROID HORMONE RECEPTOR MODULATORS | ALIGOS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022099044-A1 | 2-PYRIDONES AS THYROID HORMONE RECEPTOR MODULATORS | ALIGOS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| US-20220143032-A1 | 2-PYRIDONES AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143032-A1 | 2-PYRIDONES AND METHODS OF USE THEREOF | PSEN2, MAPT, PNPO | THRB 1462/4885THRA 2147/4885RORC 405/4885 |
| US-11786532-B2 | 2-pyridones and methods of use thereof | PSEN2, MAPT, PNPO | THRB 1462/4885THRA 2147/4885RORC 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.